Abstract
(Anaesthesia. 2020;75:1469–1475) Anaphylaxis is an immunoglobulin E–mediated event that occurs without warning after exposure to an inciting antigen. In pregnancy, this rare condition may result in severe maternal and fetal morbidity and mortality, as it has multisystemic effects. Limited high-quality studies exist regarding anaphylaxis during pregnancy. As the occurrence is rare in a single nation’s population, this European multinational study used prospective and retrospective data collection methods to estimate the causative agents, incidence, management, and outcomes of anaphylaxis during pregnancy.
Highlights
Anaphylaxis is a severe immune hypersensitivity disorder that is rapid in onset and occurs without premonitory signs
The majority of the literature on anaphylaxis in pregnancy consists of case series and case reports, with limited high quality studies [1, 2]
As anaphylaxis in pregnancy is very rare, national studies from small populations may not accrue sufficient cases unless they are conducted for long periods; on the other hand, multinational studies are able to provide larger numbers that enable more precise estimates of incidence [5]
Summary
Anaphylaxis is a severe immune hypersensitivity disorder that is rapid in onset and occurs without premonitory signs. The majority of the literature on anaphylaxis in pregnancy consists of case series and case reports, with limited high quality studies [1, 2]. There are no population-based studies examining anaphylaxis in pregnancy in continental European countries. As anaphylaxis in pregnancy is very rare, national studies from small populations may not accrue sufficient cases unless they are conducted for long periods; on the other hand, multinational studies are able to provide larger numbers that enable more precise estimates of incidence [5]. This study aimed to estimate the incidence, causative agents, management and outcomes of anaphylaxis in pregnancy across Europe using both prospective and retrospective data collection methods
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
